ライフサイエンスコーパス: magnesium sulfate

1 7-TBI, 2000 mM NaLac and 8-TBI-500 mM NaLac+magnesium sulfate.

2 factors, hypothermia, and administration of magnesium sulfate.

3 t or had acute osmotic diarrhea induced with magnesium sulfate.

4 thanks to the photoprotective properties of magnesium sulfate.

5 ence of CP or MR than those not exposed (CP: magnesium sulfate, 0.9%, no magnesium sulfate, 7.7%, cru

6 dds ratio [OR], 0.11, 95% CI, 0.02-0.81; MR: magnesium sulfate, 1.8%, no magnesium sulfate, 5.8%, cru

7 Patients received a "test dose" of either magnesium sulfate (2 g, 8 mmol) or placebo (5% dextrose

8 ly to have a seizure than those who received magnesium sulfate (21 of 819 [2.6 percent] vs. 7 of 831

9 Intravenous magnesium sulfate (4 g) was compared with placebo.

10 , 0.02-0.81; MR: magnesium sulfate, 1.8%, no magnesium sulfate, 5.8%, crude OR, 0.30, 95% CI, 0.07-1.

11 not exposed (CP: magnesium sulfate, 0.9%, no magnesium sulfate, 7.7%, crude odds ratio [OR], 0.11, 95

12 Magnesium sulfate administered according to the above re

13 Intravenous magnesium sulfate administered to pregnant individuals b

14 ween 24 and 31 weeks of gestation to receive magnesium sulfate, administered intravenously as a 6-g b

15 ical and experimental evidence as to whether magnesium sulfate, administered soon before premature bi

16 re were no complications associated with the magnesium sulfate administration.

17 tests the hypothesis that administration of magnesium sulfate, an antagonist of the NMDA receptor io

18 ors found no association between exposure to magnesium sulfate and cerebral palsy risk (odds ratio =

19 basaltic rocks, sulfate minerals (including magnesium sulfate and jarosite) that constitute several

20 Comparing the magnesium sulfate and placebo groups revealed no statist

21 :water (2:1) as extraction solvent and dried magnesium sulfate and sodium chloride as salts.

22 added to the botanical along with anhydrous magnesium sulfate and sodium chloride for extraction, fo

23 th acetonitrile after the addition of salts (magnesium sulfate and sodium chloride), followed by a cl

24 After salting out by shaking with anhydrous magnesium sulfate and sodium chloride, 1 mL of acetonitr

25 ry spectra of hydrated salt minerals such as magnesium sulfates and sodium carbonates and mixtures of

26 ate timing of administration of steroids and magnesium sulfate, and in expectant management decisions

27 tion of only monthly data on availability of magnesium sulfate, and is limited by the lack of demogra

28 pharmacologic interventions (aminophyllines, magnesium sulfate, anti-inflammatory agents, inhaled cor

29 0-500 mg IV thiamine every 8 hours, 64 mg/kg magnesium sulfate (approximately 4-5 g for most adult pa

30 There was no detectable association between magnesium sulfate availability and the rate of eclampsia

31 hical regions in 8 countries, in relation to magnesium sulfate availability.

32 es, generated during deposition of overlying magnesium sulfate-bearing strata.

33 Fetal exposure to magnesium sulfate before anticipated early preterm deliv

34 Research suggests that fetal exposure to magnesium sulfate before preterm birth might reduce the

35 hose found on Europa, that is, mostly frozen magnesium sulfate brines that are derived from a subsurf

36 geological environment that contains borate, magnesium, sulfate, calcium, and phosphate in evaporite

37 The photoprotective behavior of hydrated magnesium sulfate corroborates the hypothesis that sulfa

38 lic and mellitic acid embedded into hydrated magnesium sulfate do not change for UV exposures corresp

39 t appear to be due to selective mortality of magnesium sulfate-exposed infants.

40 t, there was no association between prenatal magnesium sulfate exposure and infant mortality (adjuste

41 rs examined the relation between intrapartum magnesium sulfate exposure and risk of cerebral palsy in

42 arily, to investigate the effect of prenatal magnesium sulfate exposure on VLBW infant mortality.

43 Data on magnesium sulfate exposure, labor and delivery, and infa

44 ng VLBW children is associated with prenatal magnesium sulfate exposure.

45 ension (181 [1%] of 20 819) or intramuscular magnesium sulfate for pre-eclampsia (198 [1%]), of whom

46 ommending administration of intravenous (IV) magnesium sulfate for refractory pediatric asthma, the n

47 ne whether nimodipine is more effective than magnesium sulfate for seizure prophylaxis in women with

48 l (PEG)/dextran (DEX)) and polymer/salt (PEG/Magnesium sulfate) for droplet generation in a flow-focu

49 Magnesium sulfate given to pregnant women at imminent ri

50 Antenatal magnesium sulfate given to pregnant women at imminent ri

51 (60 mg orally every 4 hours) or intravenous magnesium sulfate (given according to the institutional

52 ccurred significantly less frequently in the magnesium sulfate group (1.9% vs. 3.5%; relative risk, 0

53 y rate to school age was 14% (88/629) in the magnesium sulfate group and 18% (110/626) in the placebo

54 tcome was not significantly different in the magnesium sulfate group and the placebo group (11.3% and

55 More women in the magnesium sulfate group than in the nimodipine group nee

56 ong Atlanta-born survivors, those exposed to magnesium sulfate had a lower prevalence of CP or MR tha

57 Statins, endothelin antagonists, and magnesium sulfate infusion are among the novel strategie

58 Magnesium sulfate is more effective than nimodipine for

59 Magnesium sulfate is neuroprotective in preclinical mode

60 Notably, pretreatment of pregnant dams with magnesium sulfate is sufficient to prevent the early inf

61 radish peroxidase, starch, vitamin K, hemin, magnesium sulfate, manganese sulfate, and horse serum.

62 Magnesium sulfate may prevent eclampsia by reducing cere

63 sample preparation, diluting the sample with magnesium sulfate (MgSO(4)) previous to COD determinatio

64 Based on preclinical investigations, magnesium sulfate (MgSO4) has gained interest as a neuro

65 Understanding the effect of antenatal magnesium sulfate (MgSO4) treatment on functional connec

66 rose, and shikimic acid) and inorganic gels (magnesium sulfate, MgSO4).

67 e unusual areas are consistent with hydrated magnesium sulfates mixed with dark background material,

68 omized to receive either placebo (n = 15) or magnesium sulfate (n = 17).

69 3 nebulized albuterol treatments with either magnesium sulfate (n = 410) or 5.5% saline placebo (n =

70 xynaphthalene and benzo[a]pyrene in hydrated magnesium sulfate, one of the main sulfate phases presen

71 ebulized treatments of albuterol plus either magnesium sulfate or 5.5% saline placebo.

72 e occurred after in-community treatment with magnesium sulfate or during transport to facility.

73 spected stroke to receive either intravenous magnesium sulfate or placebo, beginning within 2 hours a

74 igned to Ca/Mg (1g calcium gluconate plus 1g magnesium sulfate pre- and post-oxaliplatin) or placebo,

75 a 2-mL centrifuge tube containing anhydrous magnesium sulfate, primary secondary amine sorbent, and

76 Administration of intravenous magnesium sulfate prior to preterm birth at 30 to 34 wee

77 xynaphthalene and benzo[a]pyrene in hydrated magnesium sulfate remain unaltered when exposed to UV ra

78 Patients receiving magnesium sulfate showed a statistically significant inc

79 Intravenous magnesium sulfate therapy (40-75 mg/kg).

80 Prehospital initiation of magnesium sulfate therapy was safe and allowed the start

81 Continuous nebulization, addition of magnesium sulfate to SABA, and levosalbutamol compared t

82 However, in the magnesium sulfate-treated group the Bax:Bcl-2 ratio was

83 c controls (Nx), untreated hypoxic (Hx), and magnesium sulfate-treated hypoxic (Mg-Hx) groups.

84 We suggest that magnesium sulfate treatment before and during hypoxia ma

85 The data demonstrate that magnesium sulfate treatment prevents both the hypoxia-in

86 On average, magnesium sulfate was available in 74.7% of facilities (

87 associated with nimodipine, as compared with magnesium sulfate, was 3.2 (95 percent confidence interv

88 onal studies have reported an association of magnesium sulfate with lower rate of cerebral palsy, whe

89 ters in Australia and New Zealand, comparing magnesium sulfate with placebo given to pregnant women (